{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-045371","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.108632+00:00","generated_at":"2026-05-30T00:37:32.128493+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ZyVersa Q3 net loss $2.4M, cash only $0.1M; Phase 2a trial expected Q1 2025","bullets":["Net loss improved 17.3% to $2.4M from $2.9M YoY; R&D and G&A expenses decreased.","Cash at Sept 30, 2024: $0.1M; company will need additional financing on a month-to-month basis.","Phase 2a trial for VAR 200 in diabetic kidney disease expected to begin Q1 2025 with data mid-2025.","IC 100 IND submission planned for Q2 2025; Phase 1 trial in overweight subjects planned Q2/Q3 2025.","Raised ~$3.9M from Q3 2024 to present; formed new Obesity, Metabolic & Inflammatory Disease SAB."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-045371","json":"https://secwatch.observer/filing/0001493152-24-045371.json","markdown":"https://secwatch.observer/filing/0001493152-24-045371.md","text":"https://secwatch.observer/filing/0001493152-24-045371.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315224045371/0001493152-24-045371-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315224045371/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:37:32.128493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}